Radiofrequency ablation: Identification of the ideal patient

Hiran C. Fernando, Alberto De Hoyos, Virginia Litle, Chandra P. Belani, James D. Luketich

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Radiofrequency (RF) ablation (RFA) is a relatively new modality that is being used for lung tumors with increasing frequency. Radiofrequency energy consists of an alternating current that moves from an active electrode that is placed within the tumor to dispersive electrodes that are placed on the patient. As the RF energy is applied, frictional heating of tissues results, with cell death occurring at temperatures > 60°C. This article discusses preclinical and early clinical experience with RFA for lung tumors. Radiofrequency ablation has been used for patients with primary lung cancer and limited pulmonary metastases. Current data suggest that RFA is most suitable for tumors ≤ 4 cm in size and is better for peripheral rather than centrally based nodules. Additionally, studies of RFA followed by resection have demonstrated a learning-curve effect with improved tumor kill in the later cases performed in these series. Surgical resection should continue to be the primary modality offered to patients with early-stage non-small-cell lung cancer and limited metastatic disease to the lungs (when the primary tumor is controlled). Radiofrequency ablation is a good option for those patients who are believed to be at increased risk for resection or who refuse resection, when operation would otherwise be appropriate therapy. Additionally, RFA may be used for local control of peripheral tumors in patients with more advanced cancers in combination with other therapies.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
JournalClinical Lung Cancer
Volume6
Issue number3
DOIs
StatePublished - Nov 2004

Fingerprint

Neoplasms
Lung
Electrodes
Learning Curve
Non-Small Cell Lung Carcinoma
Heating
Lung Diseases
Lung Neoplasms
Cell Death
Neoplasm Metastasis
Temperature
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Fernando, Hiran C. ; De Hoyos, Alberto ; Litle, Virginia ; Belani, Chandra P. ; Luketich, James D. / Radiofrequency ablation : Identification of the ideal patient. In: Clinical Lung Cancer. 2004 ; Vol. 6, No. 3. pp. 149-153.
@article{dde08cd2e93644b8875016bd1e68ee78,
title = "Radiofrequency ablation: Identification of the ideal patient",
abstract = "Radiofrequency (RF) ablation (RFA) is a relatively new modality that is being used for lung tumors with increasing frequency. Radiofrequency energy consists of an alternating current that moves from an active electrode that is placed within the tumor to dispersive electrodes that are placed on the patient. As the RF energy is applied, frictional heating of tissues results, with cell death occurring at temperatures > 60°C. This article discusses preclinical and early clinical experience with RFA for lung tumors. Radiofrequency ablation has been used for patients with primary lung cancer and limited pulmonary metastases. Current data suggest that RFA is most suitable for tumors ≤ 4 cm in size and is better for peripheral rather than centrally based nodules. Additionally, studies of RFA followed by resection have demonstrated a learning-curve effect with improved tumor kill in the later cases performed in these series. Surgical resection should continue to be the primary modality offered to patients with early-stage non-small-cell lung cancer and limited metastatic disease to the lungs (when the primary tumor is controlled). Radiofrequency ablation is a good option for those patients who are believed to be at increased risk for resection or who refuse resection, when operation would otherwise be appropriate therapy. Additionally, RFA may be used for local control of peripheral tumors in patients with more advanced cancers in combination with other therapies.",
author = "Fernando, {Hiran C.} and {De Hoyos}, Alberto and Virginia Litle and Belani, {Chandra P.} and Luketich, {James D.}",
year = "2004",
month = "11",
doi = "10.3816/CLC.2004.n.027",
language = "English (US)",
volume = "6",
pages = "149--153",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",

}

Fernando, HC, De Hoyos, A, Litle, V, Belani, CP & Luketich, JD 2004, 'Radiofrequency ablation: Identification of the ideal patient', Clinical Lung Cancer, vol. 6, no. 3, pp. 149-153. https://doi.org/10.3816/CLC.2004.n.027

Radiofrequency ablation : Identification of the ideal patient. / Fernando, Hiran C.; De Hoyos, Alberto; Litle, Virginia; Belani, Chandra P.; Luketich, James D.

In: Clinical Lung Cancer, Vol. 6, No. 3, 11.2004, p. 149-153.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radiofrequency ablation

T2 - Identification of the ideal patient

AU - Fernando, Hiran C.

AU - De Hoyos, Alberto

AU - Litle, Virginia

AU - Belani, Chandra P.

AU - Luketich, James D.

PY - 2004/11

Y1 - 2004/11

N2 - Radiofrequency (RF) ablation (RFA) is a relatively new modality that is being used for lung tumors with increasing frequency. Radiofrequency energy consists of an alternating current that moves from an active electrode that is placed within the tumor to dispersive electrodes that are placed on the patient. As the RF energy is applied, frictional heating of tissues results, with cell death occurring at temperatures > 60°C. This article discusses preclinical and early clinical experience with RFA for lung tumors. Radiofrequency ablation has been used for patients with primary lung cancer and limited pulmonary metastases. Current data suggest that RFA is most suitable for tumors ≤ 4 cm in size and is better for peripheral rather than centrally based nodules. Additionally, studies of RFA followed by resection have demonstrated a learning-curve effect with improved tumor kill in the later cases performed in these series. Surgical resection should continue to be the primary modality offered to patients with early-stage non-small-cell lung cancer and limited metastatic disease to the lungs (when the primary tumor is controlled). Radiofrequency ablation is a good option for those patients who are believed to be at increased risk for resection or who refuse resection, when operation would otherwise be appropriate therapy. Additionally, RFA may be used for local control of peripheral tumors in patients with more advanced cancers in combination with other therapies.

AB - Radiofrequency (RF) ablation (RFA) is a relatively new modality that is being used for lung tumors with increasing frequency. Radiofrequency energy consists of an alternating current that moves from an active electrode that is placed within the tumor to dispersive electrodes that are placed on the patient. As the RF energy is applied, frictional heating of tissues results, with cell death occurring at temperatures > 60°C. This article discusses preclinical and early clinical experience with RFA for lung tumors. Radiofrequency ablation has been used for patients with primary lung cancer and limited pulmonary metastases. Current data suggest that RFA is most suitable for tumors ≤ 4 cm in size and is better for peripheral rather than centrally based nodules. Additionally, studies of RFA followed by resection have demonstrated a learning-curve effect with improved tumor kill in the later cases performed in these series. Surgical resection should continue to be the primary modality offered to patients with early-stage non-small-cell lung cancer and limited metastatic disease to the lungs (when the primary tumor is controlled). Radiofrequency ablation is a good option for those patients who are believed to be at increased risk for resection or who refuse resection, when operation would otherwise be appropriate therapy. Additionally, RFA may be used for local control of peripheral tumors in patients with more advanced cancers in combination with other therapies.

UR - http://www.scopus.com/inward/record.url?scp=10244251529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244251529&partnerID=8YFLogxK

U2 - 10.3816/CLC.2004.n.027

DO - 10.3816/CLC.2004.n.027

M3 - Review article

C2 - 15555215

AN - SCOPUS:10244251529

VL - 6

SP - 149

EP - 153

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -